Prostate Cancer Clinical Trial

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Summary

This study investigates ways to detect prostate cancer earlier in men who are at increased genetic risk of developing prostate cancer that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

View Full Description

Full Description

OUTLINE:

Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

People with prostates ≥40 years of age
Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.

Exclusion Criteria:

Prior diagnosis of prostate cancer
Medical contraindication to any of the study procedures (e.g., prostate biopsy)
For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
Unable to provide written informed consent
Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.

Study is for people with:

Prostate Cancer

Estimated Enrollment:

450

Study ID:

NCT04472338

Recruitment Status:

Recruiting

Sponsor:

University of Washington

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

OHSU Knight Cancer Institute
Portland Oregon, 97239, United States More Info
Alexandra Sokolova, MD
Contact
503-494-7999
Alexandra Sokolova, MD
Principal Investigator
University of Pennsylvania/Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States More Info
Kara Maxwell, MD, PhD
Contact
215-615-3004
[email protected]
Kara Maxwell, MD, PhD
Principal Investigator
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States More Info
Michael Liss, MD
Contact
210-567-1100
[email protected]
Michael Liss, MD
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Seattle Washington, 98109, United States More Info
Study Team Coordinator
Contact
206-598-0850
[email protected]
Heather H. Cheng, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

450

Study ID:

NCT04472338

Recruitment Status:

Recruiting

Sponsor:


University of Washington

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.